Flaviviruses have been important human pathogens after emerging and resurging flavivirus diseases over the past decades. Although effective therapeutic agents are not yet commercially available for use in humans, significant progress has been made toward developing effective therapeutics and treatments. Several studies have shown that antibodies against the flaviviral E and NS1 proteins play a central role in prophylaxis and/or treatment of flavivirus infection through passive immunization. In addition, many anti-flavivirals, including interferons, oligonucleotide-based platforms, and small compounds, have been developed and evaluated for their antiviral effects. This review provides an overview of various approaches to the development of anti-flaviviral candidates and new insights that could improve our strategies for designing effective therapeutics against flaviviruses.
other NS proteins, NS3 and NS5, have been characterized as the viral protease/helicase and RNA-dependent RNA polymerase, respectively, which form a viral replication complex with other NS proteins (31, 32) .
Although advances in anti-flaviviral drug discovery have progressed significantly, no therapeutic agent for flavivirus infection is currently approved for human use. Recent studies suggest that monoclonal antibody (mAb)-based therapy could be a promising alternative strategy (33~36).
Several groups have generated protective mAbs against the E and NS1 proteins of flaviviruses (33, 34, 37~44) . The structural E protein is used as the major antigenic target to raise neutralizing antibodies (33, 35, 36, 45) . However, it is difficult to generate neutralizing antibody for variant viruses due to the high mutation rate of the flavivirus RNAdependent RNA polymerase (46) . Sub-neutralizing concentrations of anti-E antibody also have theoretical potential to cause antibody-dependent enhancement (ADE) of flavivirus infection (47~50). Another major antigen, the flavivirus NS1 glycoprotein, induces the production of non-neutralizing protective antibodies (34, 51~53) . Although the protective mechanisms and binding regions of a few anti-NS1 antibodies have been demonstrated (24, 34, 54~56) , most still remain to be characterized. On the other hand, several antiviral agents have been tested to overcome the drawback for anti-flavivirus antibodies (57~63). Some of these agents inhibit flavivirus infection and reduce the significant mortality and morbidity associated with the infections (62, 63) .
This review provides an overview of the major antiflavivirus antibodies and other anti-flaviviral agents with particular attention to: [1] protective and/or therapeutic antibodies against flavivirus infections, [2] the inhibitory mechanisms of protective and/or therapeutic antibodies, and [3] other candidates for anti-flavivirus therapeutics.
I. Protective antibodies against flavivirus infection
Flavivirus infection induces the humoral immune response in the host and elicits the production of anti-flavivirus antibodies that could limit viral spread and burden (64~69). As expected, many studies demonstrate that passive administration of polyclonal or monoclonal antibodies against flavivirus proteins protects mice from lethal flavivirus infection (33, 34, 37~44) , and B-celldeficient mice are more vulnerable to infection (66) . These findings indicate that antibodies are one of the major components involved in protection against flavivirus infection.
Neutralizing antibodies against the E protein
A flavivirus virion consists of three structural proteins (C, prM/M, and E), the viral genome, and a lipid envelope derived from the endoplasmic reticulum (ER) (70, 71) . The viral particle induces the production of neutralizing anti- (78) . Domain III (DIII) has an immunoglobulin-like fold and is located on the opposite end of DI, which is suggested to contain cellular receptor binding sites (43, 79, 80) . Although neutralizing mAbs that cross-react with flaviviruses primarily recognize DII, most neutralizing antibodies bind to epitopes in the DIII region ( Fig. 1) (43, 44, 81~83) . In addition, X-ray crystallography and neutralization escape mutant analysis indicate that type-specific neutralizing antibodies against individual flaviviruses mainly map to amino acid residues in DIII of the E protein ( Fig. 1 To avoid the potential ADE, recent studies engineered anti-flavivirus antibodies with mutations in the Fc region, which prevented ADE in vitro and in vivo (88) . Therefore, these findings suggest that ADE of flavivirus infection is a serious consideration in the design of novel strategies to develop a safe and effective therapeutic agent based on anti-E antibodies.
Non-neutralizing antibodies against the NS1 protein
During the course of natural infection, flaviviruses secrete nonstructural protein NS1, which is present at high concentrations (e.g., 1~50 μg/ml) in patient serum and associates with cell surface membranes (20~23, 25). Although most neutralizing antibodies are raised against virion-associated proteins, E and prM/M, NS1, which is absent from the virion, induces the production of non-neutralizing protective antibodies. Many studies have demonstrated the immunogenicity and protective efficiency of recombinant NS1 generated through DNA vaccines, recombinant viruses, and bacterial expression (38, 39, 51, 52, 91) . The passive administration of anti-NS1 antibody protects mice against lethal flavivirus challenge, depending on the dosage and time of administration (34) . These results suggest that anti-NS1 antibodies could serve as therapeutic antibodies that do not induce ADE. However, a recent study revealed that anti-DENV-2 NS1 mAbs (e.g., 1G5.3) cross-reacts with the DENV-2 E protein, inducing weak neutralizing activity and ADE in mice. These findings imply a potential risk of anti-NS1 antibody-based therapeutics (92) .
Because mapping of protective mAbs could provide useful information for the design of effective therapeutics, several studies have been performed to determine the binding regions for anti-NS1 mAbs by using overlapping peptides, bacterially expressed fragments of NS1, yeast surface display expression, and mAb competition binding assays (24, 34, 54~56) . Despite the intense interest, few protective mAbs against NS1 have been mapped to specific amino acids (53, 54, 91) Beyond direct neutralization of anti-flavivirus E mAbs, recent observations suggest that the protective activity of some neutralizing mAbs is partially dependent on the Fc portion of the mAbs and is associated with Fc receptors and the complement cascade ( Fig. 3B) (48, 82, 105) . For example, the protective efficiency of an anti-WNV E mAb is reduced in mice with blocked Fc-γ receptors I, III, and IV (82) . The neutralization potential of hu-E16 anti-WNV E is augmented by C1q, which is dependent on the isotype of antibodies that bind C1q avidly (human IgG1 and IgG3) (48) . Taken together, these recent findings suggest that a better comprehension of the role on protective antibodies in vivo and in vitro is crucial for the development of optimal therapeutic antibodies.
III. Other potential anti-flaviviral agents
Although antibody-based therapy provides a promising strategy to inhibit flavivirus infection, one possible limitation of this therapeutic antibody is the emergence of escape mutants that could decrease the inhibitory activity (46) .
Several antiviral agents have been tested and characterized
to determine their inhibitory activity against viral replication in host cells (57~63). However, it is more difficult to develop specific antiviral agents without toxicity to cells because viruses, unlike bacteria, are obligate intracellular parasites that are dependent on the host's biosynthetic machinery. In this section, several anti-flaviviral agents will be discussed.
Interferons
Interferons are produced through the innate immune response to viral infection (106) (111) . Type I interferon-pretreatment of cells also significantly inhibits flaviviruses (107~109, 111). However, the antiviral activity of interferon is significantly reduced after viral replication because flavivirus nonstructural proteins interfere with interferon signaling pathway (110, 112, 113) .
Nonetheless, several lines of evidence indicate that interferon has strong potential for use as a therapeutic. For example, treatment with interferon-α yields substantial improvement in complications in SLEV and WNV encephalitis cases (114, 115) .
Nucleic acid-based inhibitors
Nucleic acid-based antiviral agents involve the use of oligonucleotides to suppress viral gene expression, including antisense-, ribozyme-and RNA interference (RNAi)-based approaches (116, 117) . These strategies selectively inhibit viral replication by targeting the expression of key viral proteins through degradation of sequence-specific singlestranded RNA (118) . RNAi is an evolutionarily conserved cellular mechanism that is initiated by double-stranded RNA (dsRNA) or micro RNA, which specifically blocks gene expression (119, 120) . In the past decade, RNAi has been widely used to inhibit flavivirus infection in cells (57, 59, 121, 122) . For example, small interfering RNA (siRNA) inhibits JEV replication (121) . In addition, pretreatment of siRNA prior to viral replication significantly reduces WNV infection (59, 122) . Recent studies show that administration of siRNA improves survival against lethal flavivirus infection in mice (62, 63) . Although these results suggest that antiviral RNAi therapy is very promising, the emergence of escape mutations in the targeted sequences may limit their efficiency.
However, the development of a new delivery method could increase their therapeutic potential and clinical applications because commonly used methods such as electroporation, lipid-based transfection reagents, and nanoparticles are less effective and not cell specific.
Small-molecule inhibitors
Viral replication is a well-organized process that is essential for effectively producing progeny viruses. Therefore, the steps of viral replication could be attractive targets for antiviral agents that inhibit viral genome replication and enzymes whose activity is crucial for viral protein processing 
